Heghine Khachatryan on VWD: A Landmark in the History of Hematology
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, sreposted from Haematologica Journal on LinkedIn:
”A Landmark in the History of Hematology
One hundred years ago, the Finnish physician Erik Adolf von Willebrand published his seminal description of hereditary pseudohemophilia, a disorder that would later bear his name as von Willebrand disease.
This groundbreaking work was the first to clearly demonstrate that:
• inherited bleeding disorders may affect both sexes,
• the clinical phenotype can differ fundamentally from classical hemophilia, and
• family-based observation and pedigree analysis are critical to understanding disorders of hemostasis.
-The original genealogical diagram, shown here, represents more than a historical artifact—it laid the scientific foundation for modern concepts of primary hemostasis, platelet–vessel wall interaction, and the role of von Willebrand factor in coagulation.
-A century later, von Willebrand’s observations continue to inform contemporary diagnostics, molecular genetics, and individualized therapeutic strategies in bleeding disorders.
This milestone reminds us that careful clinical observation remains the cornerstone of scientific progress, even in the era of advanced genomics and precision medicine.”
Quoting Haematologica Journal‘s post:
”Landmark paper in Hematology: One hundred years ago the Finnish physician Erik Adolf von Willebrand published his landmark paper on hereditary pseudohemophilia in Documents of the Finnish Society of Medicine: he had discovered the disease that nowadays we universally known by his name.”
Read the full article here.
Article: The landmark contribution by Erik von Willebrand
Authors: Riitta Lassila, Erik Berntorp

Stay updated on all scientific advances with Hemostasis Today.
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial